PERSPECTIVE THERAPEUTICS
LIVE

Serial Number

99900238

Owner

Perspective Therapeutics, Inc.

Attorney

Sandra L Etherton

Filing Date

Jun 23, 2026

Add to watchlist:

No watchlists yet
View on USPTO

PERSPECTIVE THERAPEUTICS Trademark

Serial Number: 99900238

PERSPECTIVE THERAPEUTICS is a trademark filed by Perspective Therapeutics, Inc. on June 23, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Perspective Therapeutics, Inc. (9 trademarks)

350 Hills St., Suite 106
Richland, WA 99354

Entity Type: 03

Trademark Details

Filing Date

June 23, 2026

Registration Date

Not Registered

Published for Opposition

October 20, 2026

Goods & Services

Active chemical ingredients for use in the manufacture of anti-cancer drugs; radiopharmaceutical chemical compounds for use in the manufacture of radiopharmaceutical preparations and anti-cancer drugs and for pharmaceutical research and development; radiolabeled chemical compounds comprising alpha-emitting radionuclides for use in the manufacture of radiopharmaceutical preparations and anti-cancer drugs and for pharmaceutical research and development; bifunctional chelating agents for conjugating radionuclides to targeting molecules for use in the manufacture of radiopharmaceutical preparations and anti-cancer drugs and for pharmaceutical research and development; chemical precursors for use in the manufacture of radiopharmaceuticals; chelating compounds for radiolabeling of peptides and small molecules; radioactive isotope-labeled chemical intermediates for pharmaceutical research and manufacturing

Medical and scientific research in the field of cancer treatment and diagnosis; scientific research and development services in the field of radiopharmaceuticals and nuclear medicine; scientific contract research services in the field of radiopharmaceutical drug discovery and development; preclinical research and development services relating to radiolabeled compounds for cancer therapy and diagnosis; scientific consultation services in the field of targeted radionuclide therapy; laboratory research services in the field of radiochemistry and radiopharmaceutical development; drug discovery research services in the field of oncology radiopharmaceuticals; scientific research and technological services relating to the development of targeted alpha therapy compounds; research and development services relating to theranostic radiopharmaceutical platforms

Pharmaceutical products for the treatment of cancer; radiopharmaceutical preparations for the treatment of cancer; radiopharmaceutical preparations for the diagnosis of cancer; targeted alpha therapy radiopharmaceutical preparations for the treatment of cancer comprising prostate cancer, breast cancer, pancreatic cancer, colorectal cancer, or neuroendocrine tumors; radioligand therapy preparations comprising radiolabeled targeting compounds for oncological use; radiopharmaceutical diagnostic agents for use in nuclear medicine imaging; radiopharmaceutical preparations for the treatment of cancers; radiolabeled peptide conjugates for use in cancer therapy; radiopharmaceutical preparations for theranostic applications in oncology

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 18, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 17, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 17, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 17, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 10, 2026 GNRN
NON-FINAL ACTION E-MAILED
Sep 10, 2026 GNRT
NON-FINAL ACTION WRITTEN
Sep 10, 2026 CNRT
ASSIGNED TO EXAMINER
Sep 10, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 10, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 10, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jun 23, 2026 MAFR
NEW APPLICATION ENTERED
Jun 23, 2026 NWAP